AORT
Artivion Inc
NYSE: AORT · HEALTHCARE · MEDICAL DEVICES
$23.81
-3.45% today
Updated 2026-06-05
Market cap
$971.11M
P/E ratio
80.02
P/S ratio
2.12x
EPS (TTM)
$0.25
Dividend yield
—
52W range
$19 – $48
Volume
0.7M
Artivion Inc (AORT) Insider transactions
Net insider activity
Net buying (22,569 shares)
Buy transactions
28
Sell transactions
72
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-02 | SEMEDO, ANTHONY B. | Director | Buy | 6,325 | — | — |
| 2026-05-18 | SEMEDO, ANTHONY B. | Director | Buy | 7,576 | — | — |
| 2026-05-18 | SALVESON, JON W | Director | Buy | 7,576 | — | — |
| 2026-05-18 | HOFF, ELIZABETH A | Director | Buy | 7,576 | — | — |
| 2026-05-18 | BURBANK, JEFFREY H | Director | Buy | 7,576 | — | — |
| 2026-05-18 | BULLOCK, JAMES | Director | Buy | 7,576 | — | — |
| 2026-05-18 | BORGSTROM, MARNA P | Director | Buy | 7,576 | — | — |
| 2026-05-18 | BEVEVINO, DANIEL J | Director | Buy | 7,576 | — | — |
| 2026-05-18 | ACKERMAN, THOMAS F | Director | Buy | 7,576 | — | — |
| 2026-05-14 | BORGSTROM, MARNA P | Director | Buy | 7,850 | — | — |
| 2026-03-04 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 8,962 | $38.00 | $340556.00 |
| 2026-03-03 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 2,149 | $37.78 | $81179.76 |
| 2026-03-03 | MACKIN, JAMES P | President & CEO | Sale | 17,887 | $37.78 | $675692.16 |
| 2026-03-03 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 901 | $37.78 | $34035.82 |
| 2026-03-03 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 3,843 | $37.78 | $145171.63 |
| 2026-03-03 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 4,573 | $37.78 | $172747.82 |
| 2026-03-03 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Sale | 6,316 | $37.78 | $238590.69 |
| 2026-03-02 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Buy | 21,838 | — | — |
| 2026-03-02 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 1,513 | $38.02 | $57531.67 |
| 2026-03-02 | MACKIN, JAMES P | President & CEO | Buy | 116,948 | — | — |
| 2026-03-02 | MACKIN, JAMES P | President & CEO | Sale | 14,911 | $38.02 | $566989.28 |
| 2026-03-02 | HORTON, AMY | VP, Chief Accounting Officer | Buy | 7,475 | — | — |
| 2026-03-02 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 641 | $38.02 | $24373.96 |
| 2026-03-02 | HOLLOWAY, JEAN F | SVP, General Counsel | Buy | 27,795 | — | — |
| 2026-03-02 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 2,183 | $38.02 | $83008.36 |
| 2026-03-02 | DAVIS, JOHN E | Chief Commercial Officer | Buy | 28,845 | — | — |
| 2026-03-02 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 2,784 | $38.02 | $105861.32 |
| 2026-03-02 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Buy | 40,874 | — | — |
| 2026-03-02 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Sale | 5,178 | $38.02 | $196892.93 |
| 2026-02-24 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 1,259 | $35.69 | $44937.49 |
| 2026-02-24 | MACKIN, JAMES P | President & CEO | Buy | 97,030 | — | — |
| 2026-02-24 | MACKIN, JAMES P | President & CEO | Sale | 13,936 | $35.69 | $497417.65 |
| 2026-02-24 | HORTON, AMY | VP, Chief Accounting Officer | Buy | 5,658 | — | — |
| 2026-02-24 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 830 | $35.69 | $29625.19 |
| 2026-02-24 | HOLLOWAY, JEAN F | SVP, General Counsel | Buy | 20,085 | — | — |
| 2026-02-24 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 1,668 | $35.69 | $59535.92 |
| 2026-02-24 | DAVIS, JOHN E | Chief Commercial Officer | Buy | 20,438 | — | — |
| 2026-02-24 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 2,075 | $35.69 | $74062.97 |
| 2026-02-24 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Buy | 37,482 | — | — |
| 2026-02-24 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Sale | 4,485 | $35.69 | $160083.10 |
| 2026-02-23 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 2,423 | $37.59 | $91075.72 |
| 2026-02-23 | MACKIN, JAMES P | President & CEO | Sale | 20,962 | $37.59 | $787919.66 |
| 2026-02-23 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 1,731 | $37.59 | $65064.83 |
| 2026-02-23 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 3,079 | $37.59 | $115733.45 |
| 2026-02-23 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 3,773 | $37.59 | $141819.52 |
| 2026-02-23 | BERRY, LANCE A | EVP, COO, CFO & Treasurer | Sale | 4,981 | $37.59 | $187225.83 |
| 2025-12-15 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 5,000 | $45.11 | $225550.00 |
| 2025-12-08 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 4,572 | $44.42 | $203083.67 |
| 2025-12-03 | MACKIN, JAMES P | President & CEO | Sale | 30,921 | — | — |
| 2025-12-03 | MACKIN, JAMES P | President & CEO | Buy | 30,921 | $29.62 | $915880.02 |
| 2025-12-03 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 5,267 | $45.30 | $238595.10 |
| 2025-12-03 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 2,048 | $45.30 | $92774.40 |
| 2025-12-02 | MACKIN, JAMES P | President & CEO | Sale | 30,921 | — | — |
| 2025-12-02 | MACKIN, JAMES P | President & CEO | Buy | 30,921 | $29.62 | $915880.02 |
| 2025-12-01 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 750 | — | — |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 27,075 | — | — |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 20,301 | — | — |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Buy | 27,075 | $11.03 | $298637.25 |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Buy | 20,301 | $18.44 | $374350.44 |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 18,705 | $44.91 | $840041.55 |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 14,586 | $44.92 | $655188.53 |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 8,370 | $45.35 | $379537.65 |
| 2025-11-21 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 5,715 | $45.35 | $259152.39 |
| 2025-11-20 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 2,033 | — | — |
| 2025-11-20 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 1,355 | — | — |
| 2025-11-20 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 11,888 | $44.14 | $524736.32 |
| 2025-11-20 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 2,033 | $44.32 | $90092.39 |
| 2025-11-20 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Buy | 1,355 | $11.03 | $14945.65 |
| 2025-11-18 | HOFF, ELIZABETH A | Director | Sale | 4,200 | $45.10 | $189411.60 |
| 2025-11-17 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 6,000 | $45.73 | $274380.00 |
| 2025-11-17 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 6,394 | — | — |
| 2025-11-17 | HOLLOWAY, JEAN F | SVP, General Counsel | Buy | 6,394 | $29.62 | $189390.28 |
| 2025-11-17 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 6,394 | — | — |
| 2025-11-17 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 6,394 | $45.17 | $288816.98 |
| 2025-11-14 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 6,393 | — | — |
| 2025-11-14 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 6,393 | $45.00 | $287685.00 |
| 2025-11-14 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 6,393 | — | — |
| 2025-11-14 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 6,393 | $44.67 | $285575.31 |
| 2025-11-13 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 4,993 | $45.86 | $228968.99 |
| 2025-11-13 | MACKIN, JAMES P | President & CEO | Sale | 34,210 | $45.86 | $1.57M |
| 2025-11-13 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 3,482 | $45.86 | $159677.56 |
| 2025-11-13 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 5,761 | $45.86 | $264187.94 |
| 2025-11-13 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 6,563 | $45.86 | $300966.05 |
| 2025-11-11 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 10,000 | — | — |
| 2025-11-11 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 10,000 | $46.18 | $461800.00 |
| 2025-11-10 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 2,566 | $44.62 | $114492.35 |
| 2025-11-10 | MACKIN, JAMES P | President & CEO | Sale | 17,580 | $44.62 | $784402.02 |
| 2025-11-10 | HORTON, AMY | VP, Chief Accounting Officer | Sale | 1,789 | $44.62 | $79823.39 |
| 2025-11-10 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 2,960 | $44.62 | $132072.24 |
| 2025-11-10 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 3,373 | $44.62 | $150499.89 |
| 2025-08-27 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 18,200 | — | — |
| 2025-08-27 | STANTON, MARSHALL S. | SVP, Clinical & MD Affair | Sale | 18,200 | $44.02 | $801218.60 |
| 2025-08-25 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 10,000 | — | — |
| 2025-08-25 | HOLLOWAY, JEAN F | SVP, General Counsel | Buy | 10,000 | $11.03 | $110300.00 |
| 2025-08-15 | MACKIN, JAMES P | President & CEO | Sale | 12,500 | $42.32 | $528987.50 |
| 2025-08-12 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 16,975 | — | — |
| 2025-08-12 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 16,975 | $43.01 | $730111.73 |
| 2025-08-12 | HOLLOWAY, JEAN F | SVP, General Counsel | Sale | 6,381 | $43.02 | $274497.86 |
| 2025-08-12 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 10,802 | — | — |
| 2025-08-12 | DAVIS, JOHN E | Chief Commercial Officer | Sale | 10,802 | $43.67 | $471755.75 |
Frequently asked questions
Are AORT insiders buying or selling?
Over the transactions on record, AORT insiders have been net sellers, with about $16.86M in stock sold across 72 sales, against 7 open-market purchases.
Does insider selling at AORT mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which AORT insiders are selling the most?
Recent selling is concentrated in a few names. MACKIN, JAMES P accounts for the largest share on record, with about $5.41M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.